Incyte INCY announced positive top-line results from a late-stage lymphoma study of Monjuvi/Minjuvi (tafasitamab), a ...

Lunsumio Velo is supplied as a ready-to-use, preservative-free solution in single-dose vials containing 5mg/0.5mL and 45mg/mL.

Researchers from Memorial Sloan Kettering Cancer Center (MSK) announced today that the latest results from that follicular lymphoma clinical trial have shown the three-drug combination — rituximab ...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new research study sponsored by Tempus and ...

Tempus Launches Its First Study With a Nonprofit Foundation Collaborator to Create Robust FL Dataset Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new research study sponsored by Tempus and being run in collaboration ...

Graphical abstract of the research findings, including key features of the three subtypes C1, C2 and C3.Graphical abstract of the research findings, including key features of the three subtypes C1, C2 ...

For some people, treating follicular lymphoma involves active surveillance until severe symptoms develop. For others, chemoimmunotherapy, radiation therapy, or targeted treatments may be necessary.

Follicular lymphoma is an indolent malignancy with a generally favorable prognosis, with survival often measured in decades. Yet up to 20% of patients develop early progression after starting ...

New study shows that the lengths of menstrual cycles, follicular phases (before egg release) and luteal phases (after ovulation) are all variable. The luteal phase is importantly more variable than ...

Follicular lymphoma (FL) is a chronic disease that accounts for about 20% of non-Hodgkin's lymphoma (NHL) cases. Relapsed/refractory (R/R) FL has a progressively worsening prognosis with each ...

With a new FDA nod, BeiGene has filled the follicular lymphoma approval gap for BTK inhibitors. Thursday, the FDA doled out an accelerated approval for BeiGene’s Brukinsa to be used alongside Roche’s ...